Cargando…
Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients
BACKGROUND: Active surveillance for transfusion reactions is critically important among pediatric patients undergoing chemotherapy. Among pediatric-adolescent-young-adult (AYA) hematology/oncology patients, who have been typically excluded from transfusion reaction studies, this profile remains poor...
Autores principales: | Kohorst, Mira A., Khazal, Sajad J., Tewari, Priti, Petropoulos, Demetrios, Mescher, Benjamin, Wang, Jian, Mahadeo, Kris M., Kelley, James M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490993/ https://www.ncbi.nlm.nih.gov/pubmed/32964199 http://dx.doi.org/10.1016/j.eclinm.2020.100514 |
Ejemplares similares
-
Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?
por: Brown, Brandon Douglas, et al.
Publicado: (2021) -
IMMU-07. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE
por: Brown, Brandon, et al.
Publicado: (2020) -
The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
por: Ragoonanan, Dristhi, et al.
Publicado: (2022) -
Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia
por: Sheikh, Irtiza N., et al.
Publicado: (2022) -
Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
por: Tambaro, Francesco Paolo, et al.
Publicado: (2020)